Találati lista | Tudóstér

001-es BibID:	BIBFORM089545
035-os BibID:	(WOS)000600601200003 (Scopus)85097310520
Első szerző:	Burmester, Gerd R.
Cím:	Evolving the comprehensive management of rheumatoid arthritis : identification of unmet needs and development of practical and educational tools / G. R. Burmester, J. M. Álvaro-Gracia, N. Betteridge, J. Calvo Alén, B. Combe, P. Durez, B. Fautrel, R. J. O. Ferreira, C. Gabay, A. Iagnocco, C. Montecucco, M. štergaard, S. Ramiro, A. Rubbert-Roth, T. Stamm, Z. Szekanecz, P. C. Taylor, M. van de Laar
Dátum:	2020
ISSN:	0392-856X
Megjegyzések:	Objectives: Despite availability of efficacious treatments, unmet needs still exist, preventing optimal and comprehensive management of rheumatoid arthritis (RA). Evolving the management of RA (eRA) is a European-wide educational initiative aiming to support improved patient care through practical and educational tools addressing specific unmet needs. Methods: A multidisciplinary Steering Committee (17 members, 12 countries) identified unmet needs within the management of RA and prioritised those with the greatest impact on patient outcomes. Practical educational tools addressing priority needs were then developed for dissemination and implementation by the rheumatology community across Europe. Results: Five areas of priority need were identified: increasing early recognition of RA and treatment initiation; treating RA to target; optimal, holistic approach to selection of treatment strategy, including shared decision-making; improving identification and management of comorbidities; and non-pharmacological patient management. A suite of 14 eRA tools included educational slides, best-practice guidance, self?assessment questionnaires, clinical checklists, a multidisciplinary team training exercise, an interactive patient infographic, and case scenarios. By April 2020, rheumatology professionals in 17 countries had been actively engaged in the eRA programme; in 11 countries, eRA tools were selected by national leaders in rheumatology and translated for local dissemination. A web platform, with country-specific pages, was developed to support access to the translated tools (https://www.evolvingthemanagementofra.com/). Conclusions: The eRA programme supports comprehensive management of RA across Europe through development and dissemination of practical educational tools. The eRA tools address priority needs and are available free of charge to the rheumatology community.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Rheumatoid arthritis medical education delivery of health care rheumatology patient care team
Megjelenés:	Clinical And Experimental Rheumatology. - 38 (2020), p. 1056-1067. -
További szerzők:	Álvaro-Gracia, Jose María Betteridge, Neil Calvo Alén, Jaime Combe, Bernard Durez, Patrick Fautrel, Bruno Ferreira, Ricardo J. O. Gabay, Cem Iagnocco, Annamaria Montecucco, Carlo Maurizio štergaard, Mikkel Ramiro, Sofia Rubbert-Roth, Andrea Stamm, Tanja A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Taylor, Peter C. van de Laar, Mart
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM114359
035-os BibID:	(WoS)001065800700001 (Scopus)85179996474
Első szerző:	Taylor, Peter C.
Cím:	Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases / Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Dátum:	2024
ISSN:	1462-0324 1462-0332
Megjegyzések:	Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of various immune-mediated inflammatory diseases. There are, however, key differences between these agents that could potentially translate into unique clinical profiles. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding within the catalytic cleft of the target JAK, and giving rise to distinct pharmacological characteristics. In addition, the available agents have differing selectivity for JAK isoforms, as well as off-target effects against non-JAKs. Other differences include effects on haematological parameters, DNA damage repair, reproductive toxicity and metabolism/elimination. Here we review the pharmacological profiles of the JAKis abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib and upadacitinib.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Rheumatology. - 63 : 2 (2024), p. 298-308. -
További szerzők:	Choy, Ernest Baraliakos, Xenofon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Xavier, Ricardo M. Isaacs, John D. Strengholt, Sander Parmentier, Julie M. Lippe, Ralph Tanaka, Yoshiya
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: